Agreement brings CAP and NYS CLEP-approved genotyping test to a multi-site Alzheimer’s clinical research network
PRINCETON, NJ, NEW HAVEN, CT and ORLANDO, FL, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc. (NASDAQ: NIKI), a life sciences company focused on addressing unmet medical needs through advanced genomic and biomarker testing, today announced that DiamiR Biosciences, its wholly owned subsidiary, has signed an agreement to perform apolipoprotein E (APOE) genotyping for Charter Research, a multi-site clinical research organization that conducts trials in Alzheimer’s disease, Parkinson’s disease, metabolic liver disease, psychiatric conditions, and weight management.
The APOE gene is among the most studied genetic risk factors in neurodegeneration, and APOE status is increasingly used to inform eligibility, safety monitoring, and risk stratification in Alzheimer’s disease trials. It also carries relevance for cardiovascular and lipid-related research. Under the agreement, Charter Research’s sites will be able to use Niki BioSolutions’ testing platform, which is accredited by the College of American Pathologists (CAP) and approved by the New York State Clinical Laboratory Evaluation Program (CLEP), to bring validated genotyping results into their trial operations.
Charter Research operates research centers in Orlando and The Villages, Florida, and in Chicago, Illinois, and has served as an investigative site for late-stage Alzheimer’s disease programs. The agreement pairs that site network with a laboratory partner equipped to deliver the genetic data that modern Alzheimer’s protocols increasingly require.
“APOE status has moved from a research target to a practical necessity in Alzheimer’s trials. It informs who enrolls, how participants are monitored, and how results are interpreted, making it a routine but critical step in how these studies are designed and run,” said Alidad Mireskandari, Ph.D., President and COO of Niki BioSolutions. “We are pleased to support Charter Research’s investigators and the study participants at their centers, and we see this agreement as another step in building Niki BioSolutions into a trusted testing resource for serious disease research”.
About Niki BioSolutions
Niki BioSolutions is a clinical-stage life sciences company focused on unmet medical needs, providing high-quality genomic and biomarker testing solutions to healthcare providers, research institutions, and life sciences organizations through its CLIA-certified, CAP-accredited laboratory. The company combines proprietary technologies with a commitment to scientific rigor to support precision medicine across a range of therapeutic areas. Niki BioSolutions collaborates with leading academic centers, disease foundations, and biopharma companies.
About Charter Research
Charter Research is a clinical research site network that partners with pharmaceutical companies and study volunteers to evaluate new investigational treatments. Its research centers in Orlando and The Villages, Florida, and Chicago, Illinois, conduct clinical trials in Alzheimer’s disease, Parkinson’s disease, metabolic liver disease, psychiatric conditions, and weight loss. More information is available at CharterResearch.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often use words such as “believe,” “may,” “will,” “estimate,” “target,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “propose,” “plan,” “project,” “forecast,” “predict,” “potential,” “seek,” “future,” “outlook,” and similar variations and expressions. Forward-looking statements are those that do not relate strictly to historical or current facts. Examples of forward-looking statements may include, among others, Niki BioSolutions’ ability to successfully operate its business and provide value to stockholders; Niki BioSolutions’ future financial, business and operating performance and goals; annualized recurring revenue and customer retention; ongoing or future ability to maintain or improve its financial position, cash flows, and liquidity and its expected financial needs; potential financing and ability to obtain financing; acquisition strategy and proposed acquisitions and, if completed, their potential success and financial contributions; strategy and strategic goals, including being able to capitalize on opportunities; expectations relating to Niki BioSolutions and its industry, outlook and market trends; total addressable market and serviceable addressable market and related projections; plans, strategies and expectations for increasing revenue and executing growth initiatives. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity and development of the industries in which Niki BioSolutions operates may differ materially from those made in or suggested by the forward-looking statements. Therefore, investors should not rely on any of these forward-looking statements. Factors that may cause actual results to differ materially include changes in the markets in which Niki BioSolutions operates, the financial markets, economic, business and regulatory factors, and other factors, such as Niki BioSolutions’ ability to execute on its strategies. More detailed information about risk factors can be found in the registration statement on Form S-4 filed with the Securities and Exchange Commission (the “SEC”) on October 6, 2025 (File No. 333-290742), and in other reports filed under the company’s prior name, Aptorum Group Limited, and that will be filed by Niki BioSolutions with the SEC. Niki BioSolutions does not undertake any duty to update forward-looking statements after the date of this press release.
Investor Contact:
Lytham Partners, LLC
Ben Shamsian
646-829-9701
